沙库巴曲缬沙坦防治肿瘤治疗相关心功能不全的效果分析  

Efficacy analysis of sacubitril/valsartan in the prevention and treatment of cardiac dysfunction related to tumor therapy

作　　者：林艺婷 韩晴 郭小博 张红梅 Yiting Lin;Qing Han;Xiaobo Guo;Hongmei Zhang(Fourth Cadet Brigade,Department of Basic Medicine,Xijing Hospital,The Air Force Military Medical University,Xi'an 710032,China;Sixth Cadet Brigade,Department of Basic Medicine,Xijing Hospital,The Air Force Military Medical University,Xi'an 710032,China;Department of Clinical Oncology,Xijing Hospital,The Air Force Military Medical University,Xi'an 710032,China)

机构地区：[1]空军军医大学基础医学院学员四大队,西安市710032 [2]空军军医大学基础医学院学员六大队 [3]空军军医大学西京医院肿瘤科

出　　处：《中国肿瘤临床》2024年第4期186-191,共6页Chinese Journal of Clinical Oncology

基　　金：陕西省自然科学基础研究计划课题项目(编号:2021ZJ-35);空军军医大学临床研究课题项目(编号:2021LC2212);西京医院临床研究专项课题项目(编号:XJZT24LZ15)资助。

摘　　要：目的:探讨沙库巴曲缬沙坦治疗肿瘤治疗相关心功能不全(cancer therapy-related cardiac dysfunction,CTRCD)的疗效。方法:汇总分析自建库至2023年3月发表于Pubmed、Web of Science、Cochrane Library、Medline、Embase五大数据库的沙库巴曲缬沙坦治疗CTRCD的所有文献,归纳总结用药时机、剂量、药物疗效等;梳理总结其预防CTRCD的临床研究。结果:使用沙库巴曲缬沙坦治疗CTRCD 3~12个月后,肿瘤患者NYHA心功能从Ⅱ~Ⅳ级改善为Ⅰ~Ⅱ级,LVEF上升幅度为3.0%~37.0%,NTproBNP下降幅度为280.0~65498.0 pg/mL。结论:沙库巴曲缬沙坦治疗CTRCD有效,在改善患者LVEF、GLS等指标方面具有较好的临床应用价值,使肿瘤患者抗肿瘤治疗得以继续、生存期得以延长。Objective:To investigate the efficacy of sacubitril/valsartan in the treatment of cancer therapy-related cardiac dysfunction(CTRCD).Methods:A comprehensive analysis of all the literature on sacubitril/valsartan therapy for CTRCD published in Pubmed,Web of Science,Cochrane Library,Medline,and Embase from the inception of the database up to March 2023 was conducted,summarizing the timing of drug administration,dosage,and efficacy,and further systematically summarizing the clinical studies on the use of the drug for the prevention of CTRCD.Results:After 3-12 months of treatment with sacubitril/valsartan for CTRCD,NYHA in cancer patients improved from gradeⅡ-Ⅳto gradeⅠ-Ⅱ,LVEF increased by 3.0%to 37.0%,and NT-proBNP decreased by 280.0-65498.0 pg/mL.Conclusions:The sacubitril/valsartan demonstrates efficacy in managing CTRCD and holds significant clinical utility in enhancing LVEF,GLS,and other patient indicators,thereby enabling the continuation of anti-tumor therapy and prolonging survival for cancer patients.

关 键 词：沙库巴曲缬沙坦 肿瘤治疗相关心功能不全 心力衰竭 肿瘤心脏病学 

分 类 号：R969[医药卫生—药理学]